← Leaderboards
Edward Chu
Yale University
$17,954,928
Attributed
$17,954,928
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,176,790 · 10
By mechanism
P30$22,988,949 · 4
UM1$6,006,471 · 1
R01$2,931,886 · 2
U01$2,392,084 · 1
P01$2,053,020 · 1
T32$804,380 · 1
Top collaborators
- Steven C. Almo1 shared
Most similar at Yale University
Same institution · by research overlap
- Yung-Chi Cheng$16,454,542
- Peter M Glazer$37,467,142
- Albert C Shaw$24,226,960
- Rong Fan$22,943,481
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsBaseProgramsScienceCancer TherapyClinical TrialsFundingCancer CenterCancer Center Support GrantResearch PersonnelNational Cancer InstituteDesignBiologicalBiologyPre-ClinicalCancer EpidemiologyMemberInnovationLaboratoriesTranslatingAffectDoseCatchment AreaAntineoplastic Agents
Grant awards (62)
Leadership, Planning and Evaluation$802,152
P30 · FY2025 · CA · contact PI
Developmental Funds$433,838
P30 · FY2025 · CA · contact PI
Cancer Center Support Grant$3,899,892
P30 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$741,148
P30 · FY2024 · CA · contact PI
Developmental Funds$400,844
P30 · FY2024 · CA · contact PI
Cancer Center Support Grant$4,087,971
P30 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$776,891
P30 · FY2023 · CA · contact PI
Developmental Funds$420,175
P30 · FY2023 · CA · contact PI
Core Support for Cancer Center$2,906,419
P30 · FY2022 · CA · contact PI
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)$431,130
P30 · FY2022 · CA · contact PI
Core Support for Cancer Center$334,913
P30 · FY2022 · CA · contact PI
Antigen specific strategies for treatment of HIV+ cancer patients in the Montefiore/Einstein Cancer Center Catchment Area (Immuno/microenvironment)$249,999
P30 · FY2022 · CA · contact PI
Pathogenic role of human papillomavirus (HPV) DNA integration and clonal expansion in cervical tumorigenesis$209,619
P30 · FY2022 · CA · contact PI
Core Support for Cancer Center$2,916,911
P30 · FY2021 · CA · contact PI
Core Support for Cancer Center$250,747
P30 · FY2021 · CA · contact PI
Core Support for Cancer Center$237,147
P30 · FY2021 · CA · contact PI
Core Support for Cancer Center$2,916,911
P30 · FY2020 · CA · contact PI
Core Support for Cancer Center$250,373
P30 · FY2020 · CA · contact PI
Core Support for Cancer Center$236,823
P30 · FY2020 · CA · contact PI
Novel Biologics to Treat Lung Cancer and COVID-19 Comorbidity$167,791
P30 · FY2020 · CA · contact PI
Pilot Trial of Nivolumab plus Cabozantinib for Advanced Solid Tumors in Patients with HIV infection$125,216
P30 · FY2020 · CA · contact PI
NCI ET-CTN with Phase i Emphasis at UPCI$558,964
UM1 · FY2019 · CA · contact PI
Cancer Therapeutics Program (Project-006)$35,797
P30 · FY2019 · CA · contact PI
NCI ET-CTN with Phase i Emphasis at UPCI$2,161,338
UM1 · FY2018 · CA · contact PI
Training in Cancer Therapeutics Research$73,453
T32 · FY2018 · CA · contact PI
Cancer Therapeutics Program (Project-006)$35,797
P30 · FY2018 · CA · contact PI
Cancer Therapeutics Program (Project-006)$8,614
P30 · FY2018 · CA · contact PI
Cancer Therapeutics Program (Project-006)$3,971
P30 · FY2018 · CA · contact PI
Training in Cancer Therapeutics Research$289,431
T32 · FY2017 · CA · contact PI
Cancer Therapeutics Program (Project-006)$35,797
P30 · FY2017 · CA · contact PI
NCI ET-CTN with Phase i Emphasis at UPCI$973,400
UM1 · FY2016 · CA · contact PI
ETCTN with Phase 2 Emphasis$891,704
UM1 · FY2016 · CA · contact PI
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of Irin$347,380
P01 · FY2016 · CA · contact PI
Training in Cancer Therapeutics Research$292,090
T32 · FY2016 · CA · contact PI
Cancer Therapeutics Program (Project-006)$35,976
P30 · FY2016 · CA · contact PI
NCI ET-CTN with Phase i Emphasis at UPCI$570,371
UM1 · FY2015 · CA · contact PI
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of Irin$184,919
P01 · FY2015 · CA · contact PI
Training in Cancer Therapeutics Research$149,406
T32 · FY2015 · CA · contact PI
Cancer Therapeutics Program (Project-006)$36,087
P30 · FY2015 · CA · contact PI
NCI ET-CTN with Phase i Emphasis at UPCI$850,694
UM1 · FY2014 · CA · contact PI
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of Irin$491,312
P01 · FY2014 · CA · contact PI
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of Irin$518,056
P01 · FY2013 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$254,109
U01 · FY2013 · CA · contact PI
Clinical Study of PHY906, a Novel Chinese Herbal Medicine, as a Modulator of Irin$511,353
P01 · FY2012 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$255,617
U01 · FY2012 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$255,627
U01 · FY2011 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$177,301
U01 · FY2010 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$749,856
U01 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis$699,574
U01 · FY2009 · CA · contact PI
Molecular Regulation of Translational Regulation$210,193
R01 · FY2008 · CA · contact PI
Molecular Regulation of Translational Regulation$210,193
R01 · FY2007 · CA · contact PI
Molecular Regulation of Translational Regulation$216,471
R01 · FY2006 · CA · contact PI
MOLECULAR BASIS FOR TS TRANSLATIONAL REGULATION$245,050
R01 · FY2005 · CA
Molecular Regulation of Translational Regulation$221,680
R01 · FY2005 · CA
MOLECULAR BASIS FOR TS TRANSLATIONAL REGULATION$245,050
R01 · FY2004 · CA
MOLECULAR BASIS FOR TS TRANSLATIONAL REGULATION$245,050
R01 · FY2003 · CA
MOLECULAR BASIS FOR TRANSLATIONAL REGULATION$221,517
R01 · FY2003 · CA
MOLECULAR BASIS FOR TS TRANSLATIONAL REGULATION$245,050
R01 · FY2002 · CA
MOLECULAR BASIS FOR TRANSLATIONAL REGULATION$215,063
R01 · FY2002 · CA
MOLECULAR BASIS FOR TS TRANSLATIONAL REGULATION$245,050
R01 · FY2001 · CA
MOLECULAR BASIS FOR TRANSLATIONAL REGULATION$208,800
R01 · FY2001 · CA
MOLECULAR BASIS FOR TRANSLATIONAL REGULATION$202,719
R01 · FY2000 · CA